Neuropathic pain treatment: still a challenge | Zendy

Osvaldo J. M. Nascimento | Zendy; Bruno Lima Pessôa | Zendy; Marco Orsini | Zendy; Pedro Ribeiro | Zendy; Eduardo Davidovich | Zendy; Camila Pupe | Zendy; Pedro Moreira Filho | Zendy; Ricardo Dornas | Zendy; Lucas Masiero | Zendy; Juliana Bittencourt | Zendy; Victor Hugo Bastos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neuropathic pain treatment: still a challenge

Author(s) -

Osvaldo J. M. Nascimento,

Bruno Lima Pessôa,

Marco Orsini,

Pedro Ribeiro,

Eduardo Davidovich,

Camila Pupe,

Pedro Moreira Filho,

Ricardo Dornas,

Lucas Masiero,

Juliana Bittencourt,

Victor Hugo Bastos

Publication year - 2016

Publication title -

neurology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.39

H-Index - 16

ISSN - 2035-8377

DOI - 10.4081/ni.2016.6322

Subject(s) - medicine , neuropathic pain , neuroscience , sodium channel blocker , randomized controlled trial , intensive care medicine , pharmacology , bioinformatics , sodium channel , sodium , chemistry , organic chemistry , biology

Neuropathic pain (NP) is the result of a series of conditions caused by diseases or lesions to the somatosensory system. Due to the better understanding of NP pathophysiology previously unexplored therapies have been used with encouraging results. In this group, acetyl-L-carnitine, alpha-lipoic-acid, cannabinoids, clonidine, EMA401, botulinum toxin type A and new voltage-gated sodium channel blockers, can be included. Besides, changing paradigms may occur with the advent of optogenetics and a better understanding of epigenetic regulation. We reviewed the published literature on the pharmacological treatment of NP. Despite the interesting results, randomized controlled trials are demanded the majority of the therapies previously mentioned. In spite of several studies for the relief of NP, pain control continues being a challenge

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research